Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab Plus CV301 With Maintenance Chemotherapy for Metastatic Colorectal or Pancreatic Adenocarcinoma
NCT03376659Phase 2Terminated
- Sponsor
- Georgetown University
- Start
- Aug 2018
- Primary completion
- Aug 2021
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, CV301 in colorectal adenocarcinoma, pancreatic adenocarcinoma (PDAC), sponsored by Georgetown University. Started Aug 2018; status: terminated.
02
Drugs
durvalumabCV301
03
Conditions
colorectal adenocarcinomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03376659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03376659.